RecruitingPancreatic AdenocarcinomaWeight Loss
Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status. Each patient will be tested for SIBO using Lactulose Hydrogen Breath Test. 100 patients with diagnosed pancreatic adenocarcinoma and clinically diagnosed weight loss will be enrolled in this study.
Sponsor: Cedars-Sinai Medical Center
You may qualify if…
- ✓ Men, Women, and all genders
- ✓ Individuals 18 years old or older are included.
- ✓ Patients of the study investigators and team members
- ✓ Diagnosis of pancreatic ductal adenocarcinoma
- ✓ All subjects must consent to this study
- ✓ Clinically diagnosed weight loss
You may not qualify if…
- ✕ Minors
- ✕ Pregnant Women
- ✕ Any records flagged "break the glass" or "research opt out."
- ✕ Patients who have received treatment for SIBO in the past 3 months
Where it's recruiting
California
Los Angeles
Source: ClinicalTrials.gov · NCT06988150 · last updated 2025-05-23